Skip to main content

Table 4 Mean and standard deviation (SD) scores of ESAS-r scales for each severity group (mild or moderate/severe) and for each product group (CBD/CBD or CBD/THC:CBD)

From: Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic

Mean (SD) Pain Anxiety Depression Wellbeing
Baseline (sample size) 277 270 272 268
 Overall sample 5.14 (2.57) 3.86 (3.19) 3.16 (3.08) 5.34 (2.61)
 Mild severity group 1.69 (1.1) 0.99 (1.15) 0.87 (1.18) 1.86 (1.18)
 Moderate or severe severity group 6.34 (1.7) 6.61 (1.78) 6.3 (1.86) 6.47 (1.83)
 CBD/CBD group 5.03 (2.66) 3.80 (3.21) 2.99 (3.04) 5.28 (2.72)
 CBD/THC:CBD group 5.28 (2.45) 3.95 (3.17) 3.40 (3.13) 5.42 (2.46)
FUP1 (sample size) 262 261 261 254
 Overall Sample 4.37 (2.73) 2.93 (2.95) 2.33 (2.79) 4.45 (2.6)
 Mild severity group 2.3 (2.4) 1.62 (2.08) 1.12 (1.78) 3.73 (2.75)
 Moderate or severe severity group 5.04 (2.49) 4.15 (3.09) 3.77 (3.07) 4.72 (2.5)
 CBD/CBD group 4.09 (2.67) 2.74 (2.87) 2.23 (2.71) 4.43 (2.6)
 CBD/THC:CBD group 4.75 (2.78) 3.2 (3.05) 2.47 (2.9) 4.49 (2.63)
FUP2 (sample size) 101 99 102 97
 Overall Sample 4.7 (2.7) 2.85 (3.01) 2.67 (3.02) 4.57 (2.47)
 Mild severity group 2.18 (2.43) 1.32 (1.89) 1.52 (2.31) 3.82 (2.81)
 Moderate or severe severity group 5.2 (2.47) 3.96 (3.19) 3.74 (3.26) 4.93 (2.23)
 CBD/CBD group 4.55 (2.6) 2.44 (2.68) 2.44 (2.82) 4.76 (2.22)
 CBD/THC:CBD group 4.88 (2.81) 3.08 (3.07) 2.94 (3.24) 4.36 (2.73)
  1. The CBD/THC:CBD group is composed of patients who added THC to their CBD-rich prescription during FUP1. ESAS-r scores varied between 0 and 10 for all assessed symptoms and all visits except for the anxiety scale at FUP2 for which the maximum score was 9
  2. CBD cannabidiol, FUP1 follow-up visit at 3 month, FUP2 follow-up visit at 6 month, THC Δ9-tetrahydrocannabinol